Fascioliasis is a parasitic helminth infection caused by Fasciola liver flukes. The evidence-based first-line approach centres on a specific antiparasitic agent, with treatment success confirmed through structured post-treatment monitoring.
First-line management of fascioliasis involves a specific antiparasitic agent given as a single dose, taken with a high-fat meal to enhance bioavailability. The complete dosing regimen and full clinical guidance are available in the structured protocol.
Full regimen details are in the protocol below →Treatment response is evaluated by microscopy at defined intervals following therapy. Sequential follow-up is used to confirm parasite clearance, with additional imaging considered when initial results remain positive.
WHO recommends a single 10 mg/kg oral dose of triclabendazole.
Triclabendazole should be given with high-fat foods, as this increases its serum concentration.
For individual treatment, the WHO recommendation is to use a single dose of 10 mg/kg of triclabendazole.
To evaluate the effectiveness of treatment in individual cases, it is suggested to use microscopy 10–15 days after the treatment, and repeat it after 30 days.
If the patient remains positive, this can be confirmed by ultrasound after 30–35 days.
View source ↗